Particularly, the activity of gemtuzumab, and PBD-conjugated ADCs targeting CD33 and CD123 was found to be significantly decreased in MDS/AML cell lines compared to AML cell lines derived from de novo/ TP53-wild type AML. The gene discussed is TP53; the disease is acute myeloid leukemia.